Erste Group Bank Issues Negative Outlook for Roche Earnings

Roche Holding AG (OTCMKTS:RHHBY) – Investment analysts at Erste Group Bank lowered their FY2026 earnings estimates for Roche in a research note issued on Thursday, April 2nd. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.16 per share for the year, down from their previous estimate of $3.19. The consensus estimate for Roche’s current full-year earnings is $2.81 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.36 EPS.

A number of other brokerages also recently issued reports on RHHBY. Wolfe Research reiterated an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, January 5th. TD Cowen reiterated a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. HSBC reiterated a “buy” rating and issued a $57.00 price objective on shares of Roche in a research report on Wednesday, December 10th. Finally, Argus raised Roche from a “hold” rating to a “buy” rating in a report on Monday. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $57.00.

Roche Stock Performance

Shares of OTCMKTS:RHHBY opened at $50.08 on Wednesday. The company has a 50 day moving average of $54.36 and a 200 day moving average of $50.04. Roche has a 12 month low of $34.75 and a 12 month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Curio Wealth LLC purchased a new position in shares of Roche during the third quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in Roche during the third quarter valued at about $57,000. Salomon & Ludwin LLC boosted its position in Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after buying an additional 2,053 shares during the period. Atlas Capital Advisors Inc. purchased a new stake in Roche during the fourth quarter valued at about $192,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Roche during the third quarter valued at about $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.